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THE CHALLENGE OF ASSESSING HEALTH TECHNOLOGIES EARLY IN THE
DEVELOPMENT. SYSTEMATIC LITERATURE REVIEW OF METHODS IN USE
Markiewicz K, van Til J, IJzerman MJ
University of Twente, Enschede, The Netherlands
Medical devices are being developed continuously and their developers are under
pressure to provide better evaluations of their products. Early assessment gathers
the preliminary evidence to estimate clinical, financial, organizational, and social/
ethical consequences of a particular technology. It seems a useful tool in predicting
the potential of medical devices at the stage in which it can be adapted to fit the
environment or the environment can be prepared for the technology. If the poten-
tial is low, further development can also be stopped. Although early assessment is
recognized as an important part of medical device development process, there are
many uncertainties in its nature and regarding the methods that are being used for
its purpose. OBJECTIVE: To review different methods and their use in the early
assessment of medical technologies. METHODS: An extensive systematic litera-
ture review of different early assessment methods. The authors systematically
searched: computerised databases; published bibliographies of related topics; ci-
tations in articles reviewed; and references provided by colleagues. RESULTS: We
identified 40 studies that met the inclusion criteria. 18 papers were either system-
atic literature Reviews (5) or theoretical papers (13). 10 papers were addressing
specific applications of early assessment methodologies, and 12 papers were ad-
dressing theoretical concepts combined with examples. Those 22 articles were
analysed and categorised with regard to the stage of development of the technol-
ogy, innovation type, perspective and aims of the analysis. Aims, outcome and
uncertainties with regard to the outcome of the analysis were assessed.
CONCLUSIONS: There is a need to clarify and communicate the aims and value of
early assessment methods of medical devices to developers and policy makers, if
early assessment methods are to become an integrated part of early activities in
the development process.
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THE VALUE OF CHOICE IN A COLLECTIVELY FUNDED HEALTH SYSTEM: AN
EXTENDED ANALYTICAL APPROACH TO EXAMINE THE CONFLICT BETWEEN
DECISIONS AT INDIVIDUAL AND SOCIETAL LEVEL
Espinoza MA
University of York, Heslington, York, UK
Cost-effectiveness analysis is a well recognized tool to support decisions about
resource allocation in health care, particularly in the context of collectively funded
health systems. When a new technology is restricted based on cost-effectiveness
(because it is deemed too expensive relative to its expected benefits) a potential
conflict can arise between the social interests (i.e. maximization of the population
health subject to fixed budget constraint) and individuals who want to maximize
their own health or utility. It has been previously argued that decisions that con-
sider heterogeneity add value to the health care system. On the one hand, if a
centralized decision process is implemented (e.g. NICE in the UK), subgroup anal-
ysis is appropriate. On the other hand, if a decentralized process is to be imple-
mented, the effect of unrestricted choices on the social interests must be assessed.
I have recently presented an analytical approach to estimate the expected health
forgone (or gained) as a consequence of implementing a decentralized decision
process. In the simplest case it was assumed that social planners and patients
focus on the same metric of health, i.e. patients maximise health (for example,
QALYs) and social decision makers maximise net health (net QALYs). This piece of
work examines the case where patients choose according to a different maximand.
The analysis shows that if a single and different argument of the patient’s maxi-
mization function can be identified, the expected net health benefits forgone (or
gained) from implementing unrestricted choices can be estimated as an extension
of the base-case analysis. It also highlights the role of a robust estimation of the
joint distribution of potential outcomes, discussing gaps that require further re-
search. The contribution of this analysis for policy decisions about individualized
care is illustrated with a stylized numerical example.
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Reimbursement and research decisions about the utilisation of health care inter-
ventions can be formally characterised using methods for economic evaluation.
Reimbursement decisions are informed by establishing the expected cost-effec-
tiveness of the intervention. Research decisions are informed by establishing the
expected value of additional information (the cost of uncertainty). Price negotiation
can be used to alter conclusions about the benefits of reimbursement and the need
for further research. In practice each of these elements may be considered sepa-
rately, but they could routinely be combined within a single evaluation. Previous
research has shown (i) the impact of future changes on the payoff from reimburse-
ment in the presence of irrecoverable costs and uncertainty that will be resolved
over time, and; (ii) how the reimbursement and research decisions interact in
terms of the ability to acquire additional information and the impact of delay on
the payoffs and the size of the populations that can benefit. The objective of this
paper is to bring together established methods, using a consistent set of notation,
to describe a general algebraic framework. The aim is to show systematically how
irrecoverable costs, uncertainty that can be resolved through research and uncer-
tainty that will be resolved over time can be formally incorporated in an integrated
framework to estimate both cost-effectiveness and the value of further research
that reflects the interaction between the reimbursement and research decisions.
Furthermore we show how effective price negotiation would affect the payoff and
ranking of the alternative policy options. A simple numerical example is used to
demonstrate the application of this general algebraic framework and how the re-
sults might be presented to decision makers. The advantage of a single integrated
framework is that reimbursement, research and pricing decisions can be informed
simultaneously, transparently and consistently.
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INTERNAL AND EXTERNAL VALIDITY IN ECONOMIC MODELING:
CONSIDERATIONS BASED ON A PUBLISHED EXAMPLE
Porzsolt F
University of Ulm, Ulm, Germany
OBJECTIVES: Economic modeling is an established tool used for allocation of
health care resources. Modeling was designed to demonstrate the influence of
variables on defined outcomes (e.g. cost-effectiveness) in complex systems. Valid
information for health care decisions can be obtained if five types of bias can be
avoided: selection-, performance-, attrition-, detection-, and sampling-bias. In this
study the validity of results derived from economic modeling is investigated ad-
dressing these five types of possible biases. METHODS: A published economic
model of costs and benefits of drug treatment in mild-to-moderate Alzheimer’s
disease (Guo et al., J Med Econ 2010;13:641-654) was used for this analysis. Nine
questions were asked to confirm the validity of the obtained results. Internal va-
lidity was tested by checking the first four of the above types of bias, external
validity by checking for a possible sampling bias. RESULTS: The presented model is
flawed by absence of an explicit study question. Selection bias cannot be excluded
as the patient data were obtained from pooled clinical trials and other sources.
Performance bias is likely as the outcomes in patients extracted from pooled clin-
ical trials differed considerably to the outcomes of patients treated outside of trials.
A detection bias is likely as observed data were compared with extrapolated data.
Also the external validity of the study is likely to be impaired as the patients profiles
were not derived from real world conditions but from patients enrolled in two
clinical trials. CONCLUSIONS: This appraisal shows that phrasing a study question
is essential for selection of the appropriate study method. Economic modeling is
useful to discuss models and to generate hypotheses but always implies a high risk
of bias. Therefore, results from modeling should only be accepted when internal as
well as external validity of the used method has been confirmed.
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To guide health care decision, modeling efforts have mainly focused on cost-effec-
tiveness appraisals (CEAs) between two mutually exclusive interventions. As CEAs
do not document the impact of interventions on health care budget, they are gen-
erally complemented with budget impact analysis (BIAs). BIAs provide financial
projections only and do not detail the beneficial health effect an intervention may
have on the population targeted. Additionally, decision makers may have different
and several competing preferences and priorities on what constitutes the popula-
tion health value of an intervention. A typical example is the public health impact
of large childhood vaccination campaigns. Reduction of incidence, prevalence,
hospitalizations, deaths, costs, etc. are the many criteria assessed by decision mak-
ers beyond the QALYs gained when they contemplate vaccination campaigns. In
this research, we design a transparent dynamic budget optimization model based
on a multi-criteria decision making framework. The model is a sequential multi-
birth cohort model with yearly cycle and adaptable time-horizon (from 3 years
onwards). Optimization is realized yearly based on the population outcomes
achieved the year before, the annual budget constraints and through different
combinations and weightings of decision preferences. Decision maker preferences
can be weighted on number of cases avoided, GP visits avoided, hospitalizations
avoided, length of in-hospital stay reduction, number of in-hospital beds avoided,
number of death avoided, Life-Years gain and QALYs gain. The model is intended
to address specific questions that usually emanate from decision makers con-
fronted with the introduction of mass vaccination campaigns: What is the yearly
budget needed to achieve specific public health goals? What are the yearly and
overall expected outcomes at the population level (i.e. the public health impact or
in others words, the return-on-investment in terms of public health benefit)?
Which intervention should be given additional (less) resources to maximize (mini-
mize) impact if the available budget is increased (decreased)?
PRM171
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Standard decision rules in CEA are founded on a single objective to maximise
health subject to a single and exogenous budget constraint. In essence, this is a
well-specified constrained optimisation problem. The difficulty of using mathe-
matical programming (MP) solutions to inform the allocation problem is that the
informational demands are not feasible. However, it does provide an opportunity
to evaluate the performance of simple ex-ante decision rules that have been pro-
posed, some of which are being used to make decisions about health care technol-
ogies. Different decision rules are evaluated which compare: 1) the health gained
and forgone for a new technology based on an estimate of the cost-effectiveness
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